share_log

Exicure | 8-K: Current report

Exicure | 8-K: Current report

Exicure | 8-K:重大事件
美股SEC公告 ·  08/01 16:22

Moomoo AI 已提取核心信息

Exicure, Inc., a biotechnology company, announced on August 1, 2024, that it has received a formal notice from the Nasdaq Hearings Panel, confirming the continuation of the company's listing on The Nasdaq Capital Market. This decision is contingent on Exicure demonstrating compliance with all applicable criteria for continued listing by September 16, 2024. The company, which has undergone recent restructuring and suspended its clinical and development activities, is actively working to meet the Panel's conditions to maintain its listing. Exicure is also exploring strategic alternatives to enhance stockholder value, considering its historical biotechnology assets and other opportunities. The company has cautioned that there is no guarantee of meeting the Panel's requirements within the set timeframe and acknowledges the risks of not being able to rectify existing listing deficiencies, facing additional deficiencies, and the potential delisting of its common stock from Nasdaq.
Exicure, Inc., a biotechnology company, announced on August 1, 2024, that it has received a formal notice from the Nasdaq Hearings Panel, confirming the continuation of the company's listing on The Nasdaq Capital Market. This decision is contingent on Exicure demonstrating compliance with all applicable criteria for continued listing by September 16, 2024. The company, which has undergone recent restructuring and suspended its clinical and development activities, is actively working to meet the Panel's conditions to maintain its listing. Exicure is also exploring strategic alternatives to enhance stockholder value, considering its historical biotechnology assets and other opportunities. The company has cautioned that there is no guarantee of meeting the Panel's requirements within the set timeframe and acknowledges the risks of not being able to rectify existing listing deficiencies, facing additional deficiencies, and the potential delisting of its common stock from Nasdaq.
生物技术公司Exicure于2024年8月1日宣布,已收到纳斯达克听证会议小组的正式通知,确认公司将继续在Nasdaq资本市场上市。此决定取决于Exicure在2024年9月16日之前证明符合所有适用的继续上市要求。最近经历重组并暂停其临床和开发活动的公司正在积极努力满足小组维护上市的条件。Exicure还在探索战略性的替代方案,以增强股东价值,考虑其历史生物技术资产和其他机会。公司已警告,不能确保在规定的时间范围内满足小组的要求,并承认无法修正现有上市缺陷、面临额外缺陷和其普通股被纳斯达克退市的风险。
生物技术公司Exicure于2024年8月1日宣布,已收到纳斯达克听证会议小组的正式通知,确认公司将继续在Nasdaq资本市场上市。此决定取决于Exicure在2024年9月16日之前证明符合所有适用的继续上市要求。最近经历重组并暂停其临床和开发活动的公司正在积极努力满足小组维护上市的条件。Exicure还在探索战略性的替代方案,以增强股东价值,考虑其历史生物技术资产和其他机会。公司已警告,不能确保在规定的时间范围内满足小组的要求,并承认无法修正现有上市缺陷、面临额外缺陷和其普通股被纳斯达克退市的风险。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息